YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models
YLT192 是一种新型的、口服有效的、生物利用度高的 VEGFR2 信号通路抑制剂，在临床前模型中显示出强大的抗血管生成活性和抗肿瘤疗效。
期刊:Scientific Reports
影响因子:3.9
doi:10.1038/srep06031
Xia, Yong; Song, Xuejiao; Li, Deliang; Ye, Tinghong; Xu, Youzhi; Lin, Hongjun; Meng, Nana; Li, Guobo; Deng, Senyi; Zhang, Shuang; Liu, Li; Zhu, Yongxia; Zeng, Jun; Lei, Qian; Pan, Youli; Wei, Yuquan; Zhao, Yinglan; Yu, Luoting
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
VEGF
血管生成
